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Abstract
Estimating what would be an individual’s potential response to varying levels of
exposure to a treatment is of high practical relevance for several important fields,
such as healthcare, economics and public policy. However, existing methods for
learning to estimate counterfactual outcomes from observational data are either
focused on estimating average dose-response curves, or limited to settings with only
two treatments that do not have an associated dosage parameter. Here, we present
a novel machine-learning approach towards learning counterfactual representations
for estimating individual dose-response curves for any number of treatments with
continuous dosage parameters with neural networks. Building on the established
potential outcomes framework, we introduce performance metrics, model selection
criteria, model architectures, and open benchmarks for estimating individual dose-
response curves. Our experiments show that the methods developed in this work
set a new state-of-the-art in estimating individual dose-response.
1 Introduction
Estimating dose-response curves from observational data is an important problem in many domains.
In medicine, for example, we would be interested in using data of people that have been treated in
the past to predict which treatments and associated dosages would lead to better outcomes for new
patients [1]. This question is, at its core, a counterfactual one, i.e. we are interested in predicting what
would have happened if we were to give a patient a specific treatment at a specific dosage in a given
situation. Answering such counterfactual questions is a challenging task that requires either further
assumptions about the underlying data-generating process or prospective interventional experiments,
such as randomised controlled trials (RCTs) [2–4]. However, performing prospective experiments
is expensive, time-consuming, and, in many cases, ethically not justifiable [5]. Two aspects make
estimating counterfactual outcomes from observational data alone difficult [6, 7]: Firstly, we only
observe the factual outcome and never the counterfactual outcomes that would potentially have
happened had we chosen a different treatment option. In medicine, for example, we only observe the
outcome of giving a patient a specific treatment at a specific dosage, but we never observe what would
have happened if the patient was instead given a potential alternative treatment or a different dosage
of the same treatment. Secondly, treatments are typically not assigned at random in observational
data. In the medical setting, physicians take a range of factors, such as the patient’s expected response
to the treatment, into account when choosing a treatment option. Due to this treatment assignment
bias, the treated population may differ significantly from the general population. A supervised model
naïvely trained to minimise the factual error would overfit to the properties of the treated group, and
therefore not generalise to the entire population.
To address these problems, we introduce a novel methodology for training neural networks for
counterfactual inference that extends to any number of treatments with continuous dosage parameters.
In order to control for the biased assignment of treatments in observational data, we combine our
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method with a variety of regularisation schemes originally developed for the discrete treatment
setting, such as distribution matching [8, 9], propensity dropout (PD) [10], and matching on balancing
scores [7, 11, 12]. In addition, we devise performance metrics, model selection criteria and open
benchmarks for estimating individual dose-response curves. Our experiments demonstrate that the
methods developed in this work set a new state-of-the-art in inferring individual dose-response curves.
The source code for this work is available at https://github.com/d909b/drnet.
Contributions. We present the following contributions:
• We introduce a novel methodology for training neural networks for counterfactual inference that,
in contrast to existing methods, is suitable for estimating counterfactual outcomes for any number
of treatment options with associated exposure parameters.
• We develop performance metrics, model selection criteria, model architectures, and open bench-
marks for estimating individual dose-response curves.
• We extend state-of-the-art methods for counterfactual inference for two non-parametric treatment
options to the multiple parametric treatment options setting.
• We perform extensive experiments that show that our method sets a new state-of-the-art in inferring
individual dose-response curves from observational data across several challenging datasets.
2 Related Work
Background. Causal analysis of treatment effects with rigorous experiments is, in many domains,
an essential tool for validating interventions. In medicine, prospective experiments, such as RCTs,
are the de facto gold standard to evaluate whether a given treatment is efficacious in treating a specific
indication across a population [13, 14]. However, performing prospective experiments is expensive,
time-consuming, and often not possible for ethical reasons [5]. Historically, there has therefore been
considerable interest in developing methodologies for performing causal inference using readily
available observational data [3, 11, 15–19]. The naïve approach of training supervised models to
minimise the observed factual error is in general not a suitable choice for counterfactual inference
tasks due to treatment assignment bias and the inability to observe counterfactual outcomes. To
address the shortcomings of unsupervised and supervised learning in this setting, several adaptations
to established machine-learning methods that aim to enable the estimation of counterfactual outcomes
from observational data have recently been proposed [6–10, 20–22]. In this work, we build on several
of these advances to develop a machine-learning approach for estimating individual dose-response
with neural networks.
Estimating Individual Treatment Effects (ITE). 1 Matching methods [12] are among the most
widely used approaches to causal inference from observational data. Matching methods estimate
the counterfactual outcome of a sample X to a treatment t using the observed factual outcome of
its nearest neighbours that have received t. Propensity score matching (PSM) [11] combats the
curse of dimensionality of matching directly on the covariates X by instead matching on the scalar
probability p(t|X) of receiving a treatment t given the covariates X . Another category of approaches
uses adjusted regression models that receive both the covariates X and the treatment t as inputs.
The simplest such model is Ordinary Least Squares (OLS), which may use either one model for
all treatments, or a separate model for each treatment [23]. More complex models based on neural
networks, like Treatment Agnostic Representation Networks (TARNETs), may be used to build
non-linear regression models [9]. Estimators that combine a form of adjusted regression with a model
for the exposure in a manner that makes them robust to misspecification of either are referred to as
doubly robust [24]. In addition to OLS and neural networks, tree-based estimators, such as Bayesian
Additive Regression Trees (BART) [25, 26] and Causal Forests (CF) [20], and distribution modelling
methods, such as Causal Multi-task Gaussian Processes (CMGP) [21], Causal Effect Variational
Autoencoders (CEVAEs) [22], and Generative Adversarial Nets for inference of Individualised
Treatment Effects (GANITE) [6], have also been proposed for ITE estimation.2 Other approaches,
such as balancing neural networks (BNNs) [8] and counterfactual regression networks (CFRNET) [9],
attempt to achieve balanced covariate distributions across treatment groups by explicitly minimising
1The ITE is sometimes also referred to as the conditional average treatment effect (CATE).
2See [27] and [7] for empirical comparisons of large-numbers of machine-learning methods for ITE estimation
for two and more available treatment options.
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the empirical discrepancy distance between treatment groups using metrics such as the Wasserstein
distance [28]. Most of the works mentioned above focus on the simplest setting with two available
treatment options without associated dosage parameters. A notable exception is the generalised
propensity score (GPS) [1] that extends the propensity score to treatments with continuous dosages.
In contrast to existing methods, we present the first machine-learning approach to learn to estimate
individual dose-response curves for multiple available treatments with a continuous dosage parameter
from observational data with neural networks. We additionally extend several known regularisation
schemes for counterfactual inference to address the treatment assignment bias in observational data.
To facilitate future research in this important area, we introduce performance metrics, model selection
criteria, and open benchmarks. We believe this work could be particularly important for applications
in precision medicine, where the current state-of-the-art of estimating the average dose response
across the entire population does not take into account individual differences, even though large
differences in dose-response between individuals are well-documented for many diseases [29–31].
3 Methodology
Problem Statement. We consider a setting in which we are given N observed samples X with p
pre-treatment covariates xi and i ∈ [0 . . p − 1]. For each sample, the potential outcomes yn,t(st)
are the response of the nth sample to a treatment t out of the set of k available treatment options
T = {0, ..., k − 1} applied at a dosage st ∈ {st ∈ R, at > 0 | at ≤ s ≤ bt}, where at and bt are the
minimum and maximum dosage for treatment t, respectively. The set of treatments T can have two or
more available treatment options. As training data, we receive factual samples X and their observed
outcomes yn,f (sf ) after applying a specific observed treatment f at dosage sf . Using the training
data with factual outcomes, we wish to train a predictive model to produce accurate estimates yˆt(n, s)
of the potential outcomes across the entire range of s for all available treatment options t. We refer
to the range of potential outcomes yn,t(s) across s as the individual dose-response curve of the nth
sample. This setting is a direct extension of the Rubin-Neyman potential outcomes framework [32].
Assumptions. Following [1, 33], we assume unconfoundedness, which consists of three key parts:
(1) Conditional Independence Assumption: The assignment to treatment t is independent of the
outcome yt given the pre-treatment covariates X , (2) Common Support Assumption: For all values
of X , it must be possible to observe all treatment options with a probability greater than 0, and (3)
Stable Unit Treatment Value Assumption: The observed outcome of any one unit must be unaffected
by the assignments of treatments to other units. In addition, we assume smoothness, i.e. that units
with similar covariates xi have similar outcomes y, both for model training and selection.
Metrics. To enable a meaningful comparison of models in the presented setting, we use metrics
that cover several desirable aspects of models trained for estimating individual dose-response curves.
Our proposed metrics respectively aim to measure a predictive model’s ability (1) to recover the
dose-response curve across the entire range of dosage values, (2) to determine the optimal dosage
point for each treatment, and (3) to deduce the optimal treatment policy overall, including selection
of the right treatment and dosage point, for each individual case. To measure to what degree a model
covers the entire range of individual dose-response curves, we use the mean integrated square error3
(MISE) between the true dose-response y and the predicted dose-response yˆ as estimated by the
model over N samples, all treatments T , and the entire range [at, bt] of dosages s.
MISE =
1
N
1
|T |
∑
t∈T
N∑
n=1
∫ bt
s=at
(
yn,t(s)− yˆn,t(s)
)2
ds (1)
To further measure a model’s ability to determine the optimal dosage point for each individual case,
we calculate the mean dosage policy error (DPE). The mean dosage policy error is the mean squared
error in outcome y associated with using the estimated optimal dosage point sˆ∗t according to the
predictive model to determine the true optimal dosage point s∗t over N samples and all treatments T .
DPE =
1
N
1
|T |
∑
t∈T
N∑
n=1
(
yn,t(s
∗
t )− yn,t(sˆ∗t )
)2
(2)
3A normalised version of this metric has been used in Silva [34].
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where s∗t and sˆ
∗
t are the optimal dosage point according to the true dose-response curve and the
estimated dose-response curve, respectively.
s∗t = arg max
s∈[at,bt]
yn,t(s) (3) sˆ∗t = arg max
s∈[at,bt]
yˆn,t(s) (4)
Finally, the policy error (PE) measures a model’s ability to determine the optimal treatment policy for
individual cases, i.e. how much worse the outcome would be when using the estimated best optimal
treatment option as opposed to the true optimal treatment option and dosage.
PE =
1
N
N∑
n=1
(
yn,t∗(s
∗
t∗)− yn,tˆ∗(sˆ∗tˆ∗)
)2
(5)
where
t∗ = arg max
t∈T
yn,t(s
∗
t ) (6) tˆ
∗ = arg max
t∈T
yˆn,t(sˆ
∗
t ) (7)
are the optimal treatment option according to the ground truth y and the predictive model, respectively.
Considering the DPE and PE alongside the MISE is important to comprehensively evaluate models
for counterfactual inference. For example, a model that accurately recovers dose response curves
outside the regions containing the optimal response would achieve a respectable MISE but would not
be a good model for determining the treatment and dosage choices that lead to the best outcome for
a given unit. By considering multiple metrics, we can ensure that predictive models are a capable
both in recovering the entire dose-response as well as in selecting the best treatment and dosage
choices. We note that, in general, we can not calculate the MISE, DPE or PE without knowledge of
the outcome-generating process, since the true dose-response function yn,t(s) is unknown.
Model Architecture. Model structure plays an important role in learning representations for
counterfactual inference with neural networks [7, 9, 35]. A particularly challenging aspect of training
neural networks for counterfactual inference is that the influence of the treatment indicator variable t
may be lost in high-dimensional hidden representations [9]. To address this problem for the setting
of two available treatments without dosage parameters, Shalit et al. [9] proposed the TARNET
architecture that uses a shared base network and separate head networks for both treatment options.
In TARNETs, the head networks are only trained on samples that received the respective treatment.
Schwab et al. [7] extended the TARNET architecture to the multiple treatment setting by using k
separate head networks, one for each treatment option. In the setting with multiple treatment options
with associated dosage parameters, this problem is further compounded because we must maintain not
only the influence of t on the hidden representations throughout the network, but also the influence of
the continuous dosage parameter s. To ensure the influence of both t and s on hidden representations,
we propose a hierarchical architecture for multiple treatments called dose response network (DRNet,
Figure 1). DRNets ensure that the dosage parameter s maintains its influence by assigning a head to
each of E ∈ N equally-sized dosage strata that subdivide the range of potential dosage parameters
[at, bt]. The hyperparameter E defines the trade-off between computational performance and the
resolution (b−a)E at which the range of dosage values is partitioned. To further attenuate the influence
of the dosage parameter s within the head layers, we additionally repeatedly append s to each hidden
layer in the head layers. We motivate the proposed hierarchical structure with the effectiveness
of the regress and compare approach to counterfactual inference [23], where one builds a separate
estimator for each available treatment option. Separate models for each treatment option suffer
from data-sparsity, since only units that received each respective treatment can be used to train a
per-treatment model and there may not be a large number of samples available for each treatment.
DRNets alleviate the issue of data-sparsity by enabling information to be shared both across the entire
range of dosages through the treatment layers and across treatments through the base layers.
Model Selection. Given multiple models, it is not trivial to decide which model would perform
better at counterfactual tasks, since we in general do not have access to the true dose-response to
calculate error metrics like the ones given above. We therefore use a nearest neighbour approximation
of the MISE to perform model selection using held-out factual data that has not been used for training.
We calculate the nearest neighbour approximation NN-MISE of the MISE using:
NN-MISE =
1
N
1
T
T∑
t=1
N∑
n=1
∫ bt
s=at
(
yNN(n),t(s)− yˆn,t(s)
)2
ds (8)
where we substitute the true dose-response yn,t of the nth sample with the outcome yNN(n),t of an
observed factual nearest neighbour of the nth sample at a dosage point s from the training set. Using
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Figure 1: The dose response network (DRNet) architecture with shared base layers, k intermediary
treatment layers, and k ∗ E heads for the multiple treatment setting with an associated dosage
parameter s. The shared base layers are trained on all samples, and the treatment layers are only
trained on samples from their respective treatment category. Each treatment layer is further subdivided
into E head layers (only one set of E = 3 head layers for treatment t = 0 is shown above). Each
head layer is assigned a dosage stratum that subdivides the range of potential dosages [at, bt] into E
partitions of equal width (b−a)/E. The head layers each predict outcomes yˆt(s) for a range of values
of the dosage parameter s, and are only trained on samples that fall within their respective dosage
stratum. The hierarchical structure of DRNets enables them to share common hidden representations
across all samples (base layers), treatment options (treatment layers), and dosage strata (head layers)
while maintaining the influence of both t and s on the hidden layers.
the nearest neighbour approximation of the MISE, we are able to perform model selection without
access to the true counterfactual outcomes y. Among others, nearest neighbour methods have also
been proposed for model selection in the setting with two available treatments without dosages [36].
Regularisation Schemes. DRNets can be combined with regularisation schemes developed to
further address treatment assignment bias. To determine the utility of various regularisation schemes,
we evaluated DRNets using distribution matching [9], propensity dropout [10], matching on the entire
dataset [12], and on the batch level [7]. We naïvely extended these regularisation schemes since
neither of these methods were originally developed for the dose-response setting (Appendix A).
4 Experiments
Our experiments aimed to answer the following questions:
1 How does the performance of our proposed approach compare to state-of-the-art methods for
estimating individual dose-response?
2 How do varying choices of E influence counterfactual inference performance?
3 How does increasing treatment assignment bias affect the performance of dose-response estimators?
Datasets. Using real-world data, we performed experiments on three semi-synthetic datasets with
two and more treatment options to gain a better understanding of the empirical properties of our
proposed approach. To cover a broad range of settings, we chose datasets with different outcome and
treatment assignment functions, and varying numbers of samples, features and treatments (Table 1).
All three datasets were randomly split into training (63%), validation (27%) and test sets (10%).
News. The News benchmark consisted of 5000 randomly sampled news articles from the NY Times
corpus4 and was originally introduced as a benchmark for counterfactual inference in the setting with
two treatment options without an associated dosage parameter [8]. We extended the original dataset
specification [7, 8] to enable the simulation of any number of treatments with associated dosage
parameters. The samplesX were news articles that consist of word counts xi ∈ N, outcomes ys,t ∈ R
that represent the reader’s opinion of the news item, and a normalised dosage parameter st ∈ (0, 1]
that represents the viewer’s reading time. There was a variable number of available treatment options
t that corresponded to various devices that could be used to view the News items, e.g. smartphone,
tablet, desktop, television or others [8]. We trained a topic model on the entire NY Times corpus to
model that consumers prefer to read certain media items on specific viewing devices. We defined
z(X) as the topic distribution of news item X , and randomly picked k topic space centroids zt and 2k
4https://archive.ics.uci.edu/ml/datasets/bag+of+words
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topic space centroids zst,i with i ∈ 0, 1 as prototypical news items. We assigned a random Gaussian
outcome distribution with mean µ ∼ N (0.45, 0.15) and standard deviation σ ∼ N (0.1, 0.05) to each
centroid. For each sample, we drew ideal potential outcomes from that Gaussian outcome distribution
y˜t ∼ N (µt, σt) +  with  ∼ N (0, 0.15). The dose response y˜s was drawn from a distance-weighted
mixture of two Gaussians y˜s ∼ d0N (µst,0, σst,0) + d1N (µst,1, σst,1) using topic space distances
d = softmax(D(z(X), zst,i)) and the Euclidean distance as distance metric D. We assigned the
observed treatment t using t|x ∼ Bern(softmax(κy˜ty˜s)) with a treatment assignment bias coefficient
κ and an exponentially distributed observed dosage st using st ∼ Exp(β) with β = 0.25. The true
potential outcomes ys,t = Cy˜ty˜s were the product of y˜t and y˜s scaled by a coefficient C = 50. We
used four different variants of this dataset with k = 2, 4, 8, and 16 viewing devices, and κ = 10,
10, 10, and 7, respectively. Higher values of κ indicate a higher expected treatment assignment bias
depending on y˜ty˜s, with κ = 0 indicating no assignment bias.
Mechanical Ventilation in the Intensive Care Unit (MVICU). The MVICU benchmark models
patients’ responses to different configuratations of mechanical ventilation in the intensive care
unit. The data was sourced from the publicly available MIMIC III database [37]. The samples X
consisted of the last observed measurements xi of various biosignals, including respiratory, cardiac
and ventilation signals. The outcomes were arterial blood gas readings of the ratio of arterial oxygen
partial pressure to fractional inspired oxygen PaO2/F iO2 which, at values lower than 300, are
used as one of the clinical criteria for the diagnosis Acute Respiratory Distress Syndrome (ARDS)
[38]. We modelled a mechanical ventilator with k = 3 adjustable treatment parameters: (1) the
fraction of inspired oxygen, (2) the positive end-expiratory pressure in the lungs, and (3) tidal volume.
To model the outcomes, we use the same procedure as for the News benchmark with a Gaussian
outcome function and a mixture of Gaussian dose-response function, with the exception that we
did not make use of topic models and instead performed the similarity comparisons D in covariate
space. We used a treatment assignment bias κ = 10 and a scaling coefficient C = 150. Treatment
dosages were drawn according to st ∼ N (µdose,t, 0.1), where the distribution means were defined as
µdose = (0.6, 0.65, 0.4) for each treatment.
The Cancer Genomic Atlas (TCGA). The TCGA project collected gene expression data from
various types of cancers in 9659 individuals [39]. There were k = 3 available clinical treatment
options: (1) medication, (2) chemotherapy, and (3) surgery. We used a synthetic outcome function
that simulated the risk of cancer recurrence after receiving either of the treatment options based
on the real-world gene expression data. We standardised the gene expression data using the mean
and standard deviations of gene expression at each gene locus for normal tissue in the training
set. To model the outcomes, we followed the same approach as in the MVICU benchmark with
similarity comparisons done in covariate space using the cosine similarity as distance metric D, and
parameterised with κ = 10 and C = 50. Treatment dosages in the TCGA benchmark were drawn
according to st ∼ N (0.65, 0.1).
Dataset # Samples # Features # Treatments
News 5000 2870 2/4/8/16
MVICU 8040 49 3
TCGA 9659 20531 3
Table 1: Comparison of the benchmark datasets
used in our experiments. We evaluate on three
semi-synthetic datasets with varying numbers
of treatments and samples.
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Figure 2: Analysis of the effect of choosing
various numbers of dosage strata E (x-axis) on
MISE (red), DPE (blue), PE (orange) and Time
needed for training and evaluation (black) as
calculated on the MVICU benchmark. Metrics
were normalised to the range [0, 1]. All other
hyperparameters besides E were held equal.
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Models. We evaluated DRNet, ablations, baselines, and all relevant state-of-the-art methods: k-
nearest neighbours (kNN) [12], BART [25, 26], CF [20], GANITE [6], TARNET [9], and GPS
[1] using the "causaldrf" package [40]. We evaluated which regularisation strategy for learning
counterfactual representations is most effective by training DRNets using a Wasserstein regulariser
between treatment group distributions (+ Wasserstein) [9], PD (+ PD) [10], batch matching (+ PM)
[7], and matching the entire training set as a preprocessing step [41] using the PM algorithm (+
PSMPM) [7]. To determine whether the DRNet architecture is more effective than its alternatives at
learning representations for counterfactual inference in the presented setting, we also evaluated (1) a
multi-layer perceptron (MLP) that received the treatment index t and dosage s as additional inputs,
and (2) a TARNET for multiple treatments that received the dosage s as an extra input (TARNET)
[7, 8] with all other hyperparameters beside the architecture held equal. As a final ablation of DRNet,
we tested whether appending the dosage parameter s to each hidden layer in the head networks is
effective by also training DRNets that only receive the dosage parameter once in the first hidden layer
of the head network (- Repeat). We naïvely extended CF, GANITE and BART by adding the dosage
as an additional input covariate, because they were not designed for treatments with dosages.
Hyperparameters. To ensure a fair comparison of the tested models, we took a systematic approach
to hyperparameter search. Each model was given exactly the same number of hyperparameter
optimisation runs with hyperparameters chosen at random from predefined hyperparameter ranges
(Appendix B). We used 5 hyperparameter optimisation runs for each model on TCGA and 10 on
all other benchmarks. Furthermore, we used the same random seed for each model, i.e. all models
were evaluated on exactly the same sets of hyperparameter configurations. After computing the
hyperparameter runs, we chose the best model based on the validation set NN-MISE. This setup
ensures that each model received the same degree of hyperparameter optimisation. For all DRNets
and ablations, we used E = 5 dosage strata with the exception of those presented in Figure 2.
Metrics. For each dataset and model, we calculated the
√
MISE,
√
DPE, and
√
PE. We used
Romberg integration with 64 equally spaced samples from yn,t and yˆn,t to compute the inner integral
over the range of dosage parameters necessary for the MISE metric. To compute the optimal dosage
points and treatment options in the DPE and PE, we used Sequential Least Squares Programming
(SLSQP) to determine the respective maxima of yn,t(s) and yˆn,t(s) numerically.
5 Results and Discussion
Counterfactual Inference. In order to evaluate the relative performances of the various methods
across a wide range of settings, we compared the MISE of the listed models for counterfactual
inference on the News-2/4/8/16, MVICU and TCGA benchmarks (Table 2; other metrics in Ap-
pendix D). Across the benchmarks, we found that DRNets outperformed all existing state-of-the-art
methods in terms of MISE. We also found that DRNets that used additional regularisation strategies
outperformed vanilla DRNets on News-2, News-4, News-8 and News-16. However, on MVICU and
TCGA, DRNets that used additional regularisation performed similarly as standard DRNets. Where
regularisation was effective, Wasserstein regularisation between treatment groups (+ Wasserstein) and
batch matching (+ PM) were generally slightly more effective than PSMPM and PD. In addition, not
repeating the dosage parameter for each layer in the per-dosage range heads of a DRNet (- Repeat)
performed worse than appending the dosage parameter on News-2, News-4 and News-8. Lastly, the
results showed that DRNet improved upon both TARNET and the MLP baseline by a large margin
across all datasets - demonstrating that the hierarchical dosage subdivision introduced by DRNets
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Figure 3: Comparison of DRNet (red), TARNET (blue), MLP (yellow) and GPS (purple) in terms of
their
√
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√
DPE (bottom) for varying levels of treatment assignment bias κ (x-axis) on
News-2. DRNet performs better than other methods across the entire evaluated range of treatment
assignment bias values, and is more robust to increasing levels of κ.
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Table 2: Comparison of methods for counterfactual inference with multiple parametric treatments
on News-2/4/8/16, MVICU and TCGA. We report the mean value ± the standard deviation of√
MISE on the respective test sets over 5 repeat runs with new random seeds. n.r. = not reported for
computational reasons (excessive runtime). †= significantly different from DRNet (α < 0.05).
Method News-2 News-4 News-8 News-16 MVICU TCGA
DRNet 8.0 ± 0.1 11.6 ± 0.1 10.2 ± 0.1 10.3 ± 0.0 31.1 ± 0.4 9.6 ± 0.0
- Repeat † 9.0 ± 0.1 †11.9 ± 0.2 10.3 ± 0.1 10.4 ± 0.1 31.0 ± 0.3 10.2 ± 0.2
+ Wasserstein † 7.7 ± 0.2 11.5 ± 0.0 †10.0 ± 0.0 †10.2 ± 0.0 32.9 ± 2.9 10.2 ± 0.9
+ PD † 9.0 ± 0.2 †12.2 ± 0.1 †10.6 ± 0.2 10.3 ± 0.1 †36.9 ± 0.9 †11.9 ± 1.4
+ PM † 8.4 ± 0.3 †12.2 ± 0.1 †11.4 ± 0.3 †12.3 ± 0.3 31.2 ± 0.4 9.7 ± 0.2
+ PSMPM † 8.6 ± 0.1 †12.2 ± 0.2 †11.5 ± 0.2 †12.2 ± 0.3 †32.6 ± 0.5 †11.4 ± 0.6
MLP †15.3 ± 0.1 †14.5 ± 0.0 †13.9 ± 0.1 †14.0 ± 0.0 †49.5 ± 5.1 †15.3 ± 0.2
TARNET †15.5 ± 0.1 †15.4 ± 0.0 †14.7 ± 0.1 †14.7 ± 0.1 †58.0 ± 4.8 †14.7 ± 0.1
GANITE †16.8 ± 0.1 †15.6 ± 0.1 †14.8 ± 0.1 †14.8 ± 0.0 †59.5 ± 0.8 †15.4 ± 0.2
kNN †16.2 ± 0.0 †14.7 ± 0.0 †15.0 ± 0.0 †14.5 ± 0.0 †54.9 ± 0.0 n.r.
GPS †47.6 ± 0.1 †24.7 ± 0.1 †22.9 ± 0.0 †15.5 ± 0.1 †78.3 ± 0.0 †26.3 ± 0.0
CF †26.0 ± 0.0 †20.5 ± 0.0 †19.6 ± 0.0 †14.9 ± 0.0 †57.5 ± 0.0 †15.2 ± 0.0
BART †13.8 ± 0.2 †14.0 ± 0.1 †13.0 ± 0.1 n.r. †47.1 ± 0.8 n.r.
is effective, and that an optimised model structure is paramount for learning representations for
counterfactual inference.
Number of Dosage Strata E. To determine the impact of the choice of the number of dosage strata
E on DRNet performance, we analysed the estimation performance and computation time of DRNets
trained with various numbers of dosage strata E on the MVICU benchmark (Figure 2). With all other
hyperparameters held equal, we found that a higher number of dosage strata in general improves
estimation performance, because the resolution at which the dosage range is partitioned is increased.
However, there is a trade-off between resolution and computational performance, as higher values of
E consistently increased the computation time necessary for training and prediction.
Treatment Assignment Bias. To assess the robustness of DRNets and existing methods to increas-
ing levels of treatment assignment bias in observational data, we compared the performance of DRNet
to TARNET, MLP and GPS on the test set of News-2 with varying choices of treatment assignment
bias κ ∈ [5, 20] (Figure 3). We found that DRNet outperformed existing methods across the entire
range of evaluated treatment assignment biases.
Limitations. A general limitation of methods that attempt to estimate causal effects from ob-
servational data is that they are based on untestable assumptions [2]. In this work, we assume
unconfoundedness [1, 33], which implies that one must have reasonable certainty that the available
covariate set X contains the most relevant variables for the problem setting being modelled. Making
this judgement can be difficult in practice, particularly when one does not have much prior knowledge
about the underlying causal process. Even without such certainty, this approach may nonetheless be a
justifiable starting point to generate hypotheses when experimental data is not available [42].
6 Conclusion
We presented a deep-learning approach to learning to estimate individual dose-response to multiple
treatments with continuous dosage parameters based on observational data. We extended several
existing regularisation strategies to the setting with any number of treatment options with associated
dosage parameters, and combined them with our approach in order to address treatment assign-
ment bias inherent in observational data. In addition, we introduced performance metrics, model
selection criteria, model architectures, and new open benchmarks for this setting. Our experiments
demonstrated that model structure is paramount in learning neural representations for counterfactual
inference of dose-response curves from observational data, and that there is a trade-off between model
resolution and computational performance in DRNets. DRNets significantly outperform existing
state-of-the-art methods in inferring individual dose-response curves across several benchmarks.
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A Treatment Assignment Bias Regularisation
To address treatment assignment bias in DRNets, we evaluated four different regularisation strategies:
(1) distribution matching between treatment groups using the Wasserstein regulariser (+ Wasserstein),
(2) propensity dropout (+ PD), (3) matching on the entire dataset, and (4) matching on the batch
level. Because neither of these regularisation strategies were originally developed for the setting with
parametric treatment options, we implemented näive extensions thereof for this setting. To extend
(1) to this setting, we followed Schwab et al. (2018) and penalised pair-wise differences between
treatment group distributions in the topmost shared hidden layer using the first treatment option as
the control treatment. For (2), we applied PD for each treatment option to both the corresponding
per-treatment layers and to the respective treatment option’s head layers in each dosage stratum. To
use (3) dataset-wide and (4) per-batch matching with parametric treatments, we followed the PM
algorithm outlined in Schwab et al. (2018), and matched directly on the covariates X with the dosage
parameter s added to the covariate set. For datasets of dimensionality higher than 200, we matched
on a low-dimensional representation obtained via Principal Components Analysis (PCA) using 50
principal components in order to reduce the computational requirements.
B Hyperparameters
We used a standardised approach to hyperparameter optimisation for all methods. Each method
was given exactly the same amount of hyperparameter optimisation runs (5 on TCGA, and 10 on
all other benchmarks). We also fixed the random seed such that all methods were evaluated on
exactly the same random hyperparameter configurations. For the methods based on neural network
models (DRNet, + Repeat, + Wasserstein, + PD, + PM, + PSMPM, MLP, TARNET, GANITE),
we chose hyperparameters at random from predefined ranges (Table S1). For "+ Wasserstein", we
additionally chose an imbalance penalty weight at random from 0.1, 1.0, or 10.0. For GANITE,
we also randomly chose the supervised loss weights α and β from 0.1, 1.0, and 10.0 (Yoon et al.,
2018) as an additional hyperparameter. For BART and CF, we used the default hyperparameters
from their respective implementations in the R-packages "bartMachine" (Kapelner & Bleich, 2013)
and "grf" (Athey et al., 2016). Because CF was designed for estimating the difference in treatment
effect between two treatment options and not for directly estimating treatment outcomes yˆt, we
used a baseline ridge regression model with regularisation strength α = 0.5 to estimate a control
outcome yˆ0 for the first treatment and one CF model to estimate the difference in treatment effect
between that control treatment and all other treatment options (Schwab et al., 2018). For KNN, we
used 5 nearest neighbours to compute the potential outcomes matching on the covariates X with the
dosage parameter s added as an additional covariate. For GPS, we used the implementation in the
"causaldrf" R-package (Galagate, 2016) with a normal treatment model, a linear treatment formula,
arXiv Preprint.
Table S1: Hyperparameter ranges used in our experiments.
Hyperparameter Values
Batch size B 32, 64, 128
Number of units per hidden layer M 24, 48, 96
Number of hidden layers L 2, 3
Dropout percentage pdropout [0.0, 0.2]
and a polynomial of degree 2 as the outcome formula. To reduce the computational requirements for
GPS to a manageable level, we additionally preprocessed the covariates X using PCA dimensionality
reduction with 16 principal components for benchmarks with a covariate-space dimensionality higher
than 200.
C Computing Infrastructure
We used computing infrastructure consisting of compute nodes with Intel i5 and Xeon CPUs to run
the experiments described in this paper.
D Dosage Policy Error and Policy Error Results
We report the Dosage Policy Error (DPE) and Policy Error (PE) results in Tables S2 and S3, respec-
tively. We found that DRNets outperformed all existing state-of-the-art methods in terms of DPE
and PE with the exception of the PE on News-8, where DRNets achieved the second-best result after
GPS.
2
Table S2: Comparison of methods for counterfactual inference with multiple parametric treatments
on News-2/4/8/16, MVICU and TCGA. We report the mean value ± the standard deviation of√
DPE on the respective test sets over 5 repeat runs with new random seeds. n.r. = not reported for
computational reasons (excessive runtime). †= significantly different from DRNet (α < 0.05).
Method News-2 News-4 News-8 News-16 MVICU TCGA
DRNet 14.0 ± 0.1 14.3 ± 0.2 17.2 ± 0.6 19.1 ± 2.1 5.0 ± 1.5 2.1 ± 0.4
- Repeat 17.5 ± 7.1 †18.5 ± 3.8 16.8 ± 2.9 16.1 ± 3.0 5.4 ± 3.1 5.4 ± 3.9
+ Wasserstein †13.8 ± 0.1 14.2 ± 0.3 16.7 ± 0.6 18.7 ± 2.4 20.3 ± 19.0 2.9 ± 1.3
+ PD †13.7 ± 0.1 14.3 ± 0.2 17.6 ± 0.0 16.5 ± 2.0 †38.9 ± 19.6 †12.7 ± 5.4
+ PM †13.7 ± 0.1 13.9 ± 0.5 †21.3 ± 2.7 21.0 ± 0.7 †12.5 ± 3.5 1.8 ± 0.1
+ PSMPM 14.0 ± 0.1 14.3 ± 0.1 †19.5 ± 1.3 19.2 ± 1.6 †28.1 ± 1.4 2.5 ± 1.1
MLP †47.1 ± 0.0 †43.2 ± 0.1 †39.8 ± 0.4 †40.7 ± 0.0 †42.8 ± 22.8 †31.1 ± 0.1
TARNET †45.0 ± 1.1 †41.5 ± 1.1 †38.6 ± 1.1 †38.1 ± 1.4 †106. ± 48.8 †38.6 ± 1.1
GANITE †39.4 ± 0.1 †35.5 ± 0.1 †32.6 ± 0.2 †32.0 ± 0.3 †103. ± 9.1 †26.5 ± 0.6
kNN †44.6 ± 0.0 †41.4 ± 0.0 †39.2 ± 0.0 †38.1 ± 0.0 †60.5 ± 0.0 n.r.
GPS †42.3 ± 0.0 †34.7 ± 0.0 †22.5 ± 0.0 17.3 ± 0.1 †81.6 ± 0.0 †23.8 ± 0.0
CF †47.1 ± 0.0 †43.2 ± 0.0 †38.3 ± 0.0 †35.2 ± 0.0 †116. ± 0.0 †30.9 ± 0.0
BART †31.6 ± 1.4 †25.0 ± 1.5 †23.1 ± 0.4 n.r. †39.9 ± 2.4 n.r.
Table S3: Comparison of methods for counterfactual inference with multiple parametric treatments
on News-2/4/8/16, MVICU and TCGA. We report the mean value ± the standard deviation of√
PE on the respective test sets over 5 repeat runs with new random seeds. n.r. = not reported for
computational reasons (excessive runtime). †= significantly different from DRNet (α < 0.05).
Method News-2 News-4 News-8 News-16 MVICU TCGA
DRNet 15.7 ± 0.2 15.5 ± 0.4 15.1 ± 0.2 19.2 ± 14.9 12.9 ± 1.2 2.1 ± 0.1
- Repeat 20.4 ± 9.6 20.0 ± 10. 24.3 ± 12. 5.3 ± 8.8 13.7 ± 2.5 2.9 ± 1.3
+ Wasserstein †15.2 ± 0.1 15.4 ± 0.5 15.6 ± 1.1 19.2 ± 14.9 13.6 ± 1.3 2.2 ± 0.0
+ PD 15.3 ± 0.6 †32.8 ± 0.0 14.9 ± 0.0 † 0.9 ± 0.0 †48.1 ± 27.1 †21.8 ± 9.2
+ PM †15.1 ± 0.1 12.4 ± 5.3 †29.3 ± 7.2 33.0 ± 11.7 12.1 ± 1.9 2.3 ± 0.4
+ PSMPM †16.2 ± 0.4 15.3 ± 0.3 †23.7 ± 7.3 † 1.3 ± 0.8 †23.3 ± 4.7 †2.3 ± 0.1
MLP †49.5 ± 0.1 †49.6 ± 0.0 †48.5 ± 0.7 †48.3 ± 0.3 †23.7 ± 9.8 †37.1 ± 2.3
TARNET †47.2 ± 2.1 †48.0 ± 1.8 †47.7 ± 1.1 †44.8 ± 3.2 †102. ± 44.0 †47.7 ± 1.1
GANITE †42.6 ± 0.3 †40.3 ± 0.3 †42.7 ± 0.4 34.4 ± 0.6 †96.7 ± 9.9 †25.9 ± 1.1
kNN †45.2 ± 0.0 †42.1 ± 0.0 †45.5 ± 0.0 †46.4 ± 0.0 †59.1 ± 0.0 n.r.
GPS †44.6 ± 0.0 †13.3 ± 0.0 †13.3 ± 0.0 †1.6 ± 0.0 †140. ± 0.0 †20.0 ± 0.0
CF †48.9 ± 0.0 †49.6 ± 0.0 †49.6 ± 0.0 †48.3 ± 0.0 †108. ± 0.0 †35.3 ± 0.0
BART †35.5 ± 14. †34.6 ± 4.2 †44.5 ± 1.2 n.r. 13.2 ± 1.0 n.r.
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